Iqvia sees FY25 EPS $11.70- $12.10, consensus $11.88

The company reaffirms its 2025 outlook of revenue growth at constant currency ex-COVID of 4 to 7% Adjusted EBITDA margin expansion of up to 20 basis points and Adjusted Diluted Earnings per Share growth of 5 to 9%. These expectations result in full-year revenue guidance of $15,725M to $16,125M, consensus 16.03B…Adjusted EBITDA of $3,765M to $3,885M, and Adjusted Diluted Earnings per Share of $11.70 to $12.10. This revenue guidance assumes just over $100M of COVID-related revenue step-down, entirely in R&DS, approximately 150 basis points of headwind from foreign exchange, and 100-150 basis points of contribution from acquisitions. All financial guidance assumes foreign currency exchange rates as of February 5, 2025 remain in effect for the forecast period.